insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

PRDS · Pardes Biosciences, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ2 '23Q3 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$6.93M$12.98M-$17.38M$6.27M$3.44M----
SG&A$5.69M$6.83M-$6.92M$7.59M$8.23M-$30.0K$40.0K$109.1K
Total Operating Expenses$12.62M$19.81M-$11.52M$8.14M$4.53M----
D&A----------
Operating Income-------($1.22M)($2.17M)($168.5K)
Interest Expense----------
Income Tax----------
Net Income($10.78M)($17.80M)-($23.34M)($27.64M)($21.44M)-($1.22M)($2.17M)($168.2K)
EPS - Basic($0.18)($0.30)-($3.76)($3.45)-----
EPS - Diluted($0.18)($0.30)-($0.40)($0.48)-----

Balance Sheet

Line itemQ2 '23Q3 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21
Cash & Equivalents$100.27M$47.16M$59.28M$209.06M$228.60M$247.92M$268.68M$16.8K$353.3K$958.4K
Accounts Receivable----------
Inventory----------
Accounts Payable$14.0K$3.71M$4.93M$1.57M$1.68M$2.37M$2.38M$183.9K$142.1K$140.2K
Current Assets$157.31M$176.15M$200.40M$214.04M$233.85M$255.14M$275.26M$570.5K$989.8K$8.8K
Total Assets$157.31M$176.15M$200.62M$214.04M$233.85M$255.14M$275.26M$201.83M$202.25M$91.7K
Current Liabilities$1.93M$11.41M$20.43M$12.03M$11.22M$8.76M$8.96M$2.50M$1.69M$67.7K
Long-term Debt----------
Total Liabilities$1.93M$11.41M$20.43M$12.03M$11.22M$8.76M$8.96M$9.54M$8.74M$67.7K
Stockholders' Equity$155.38M$164.73M$180.20M$202.01M$222.63M$246.38M$266.29M$25.0K$5.00M$5.00M
Retained Earnings($176.74M)($165.96M)($148.16M)($123.94M)($100.60M)($72.96M)($51.52M)($8.96M)($2.34M)($1.0K)

Cash Flow

Line itemQ2 '23Q3 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21
Operating Cash Flow-($26.53M)---($20.36M)---($858.2K)
Investing Cash Flow-$0-------($201.25M)
Financing Cash Flow-$0---($397.0K)---$203.06M
CapEx----------
Free Cash Flow----------

Ratios

MetricQ2 '23Q3 '23Q4 '22Q3 '22Q2 '22Q1 '22Q4 '21Q3 '21Q2 '21Q1 '21
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-6.8%-10.1%--10.9%-11.8%-8.4%--0.6%-1.1%-183.4%
Return on equity-6.9%-10.8%--11.6%-12.4%-8.7%--4871.7%-43.3%-3.4%
Return on invested capital----------
Liquidity
Current ratio81.7215.439.8117.8020.8429.1230.700.230.580.13
Quick ratio81.7215.439.8117.8020.8429.1230.700.230.580.13
Cash ratio52.094.132.9017.3820.3728.2929.970.010.2114.15
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.011.071.111.061.051.041.038073.3140.450.02
Liabilities / Assets0.010.060.100.060.050.030.030.050.040.74
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)----------
Net income growth (YoY)61.0%23.7%--1816.0%-1176.0%-12647.3%----
EPS growth (YoY)62.5%25.0%--------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-30.2%-18.5%-32.3%807952.0%4352.6%4827.6%----

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing PARDES BIOSCIENCES against the 5 most active filers in the same SIC group.